Clinical trials
Phase 1/2 Uterine Cervical Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
74 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 8 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Recruiting | 22 |
| Terminated | 12 |
| Active, not recruiting | 7 |
| Withdrawn | 2 |
| Suspended | 1 |
| Unknown status | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 10 |
| Incyte Biosciences International Sàrl | 3 |
| Agenus Inc. | 2 |
| Genmab | 2 |
| Klus Pharma Inc. | 2 |
| Radiation Therapy Oncology Group | 2 |
| Seagen Inc. | 2 |
| Advaxis, Inc. | 1 |
| Advenchen Laboratories, LLC | 1 |
| Amgen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Cervical Neoplasms | 74 |
| Ovarian Neoplasms | 32 |
| Carcinoma, Non-Small-Cell Lung | 30 |
| Endometrial Neoplasms | 27 |
| Squamous Cell Carcinoma of Head and Neck | 23 |
| Esophageal Neoplasms | 20 |
| Melanoma | 20 |
| Stomach Neoplasms | 20 |
| Breast Neoplasms | 18 |
| Carcinoma, Renal Cell | 16 |
Trials
Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.